BioSpace News Archive

Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that it has received a A$6.6 million research and development tax credit from the Australian Taxation Office.

RadNet, Inc. reported that it has acquired two unrelated Dutch technology companies, Aidence Holding B.V., a leading radiology artificial intelligence company focusing on clinical solutions for pulmonary nodule management and lung cancer screening and Quantib B.V., a leading radiology AI and machine learning company focusing on clinical solutions for prostate cancer and neurodegeneration.

SAB Biotherapeutics reported positive Phase 2 safety and efficacy data demonstrating that SAB-185 met the criteria required for advancement to Phase 3 in the US National Institutes of Health COVID-19 ACTIV-2 Trial.

Ipsen announced the Health Canada approval of Sohonos, an oral selective retinoic-acid receptor gamma agonist indicated to reduce the formation of heterotopic ossification in adults and children aged 8 years and above for females and 10 years and above for males with fibrodysplasia ossificans progressiva.1 Sohonos is approved for the treatment of patients with FOP for both chronic use, and for flare-ups, in these patient populations.

MaaT Pharma announced positive interim engraftment data from the first four cohorts of the CIMON trial with MaaT033, the Company’s high-richness, high-diversity, Microbiome Ecosystem Therapy for oral administration.

Harbour BioMed announced that, it has successfully completed the dosing of first patient in phase Ib/IIa trial at the stage of dose expansion of its anti-CTLA-4 antibody in combination therapy with toripalimab for patients suffering from advanced melanoma and other solid tumors.

ERYTECH Pharma announced presentation of results of two trials evaluating eryaspasein advanced pancreatic cancerat the American Society of Clinical Oncology Gastrointestinal Cancers Symposium on January 21, 2022.

Innovent Biologics, Inc. announced that the Hong Kong Department of Health (DH) has approved Pemazyre®.

The journal Nature Medicine recently published a study in which researchers developed a novel receptor to enhance recognition of tumors by engineered T cells, addressing an underlying cause for relapsed tumors in patients after chimeric antigen receptor therapy.

Basilea Pharmaceutica Ltd. announced that updated interim results from cohort 2 of the phase 2 study FIDES-01 were presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2022, held from January 20 to 22, in San Francisco, USA.